基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
过继性自然杀伤(NK)细胞疗法是治疗三阴性乳腺癌的一种有前景的策略,但其疗效往往受到瘤内持久性差以及在免疫抑制性肿瘤微环境中功能耗竭的限制。
英文原题:Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.
这些发现表明,协调的适应性-固有免疫动态是治疗疗效的基础,而系统性免疫耗竭和髓系免疫调节则导致耐药。
三阴性乳腺癌(TNBC)是一种侵袭性乳腺癌亚型,治疗选择有限,对免疫检查点抑制剂的应答也有限。TIL(肿瘤浸润淋巴细胞)已被广泛研究;然而,外周免疫动态与治疗应答背后的机制性调控之间的整合仍不明确。在此,我们将免疫状态建模与通路水平的机制推断相结合,分析接受紫杉醇单药或联合抗PD-L1抗体atezolizumab治疗的晚期TNBC患者PBMC的单细胞RNA测序。该框架利用治疗分组、纵向采样和临床应答,解析淋巴系和髓系区室中协调的免疫程序。我们识别出治疗前和治疗后不同的治疗特异性和应答特异性状态。化疗应答者显示出治疗前适应性免疫启动,而联合治疗应答者则表现出预先存在的效应T细胞活性,并伴有肿瘤PD-L1表达。相反,化疗无应答者在调节性和终末效应程序中出现了治疗后持续存在的免疫失调,而联合治疗无应答者则表现出适应性和固有区室的适应不良性重塑,包括功能失调的NK和代谢重编程的髓系细胞群。跨治疗方案,涉及蛋白质翻译、代谢适应和应激信号传导的通路成为应答的共同调节因素。这些发现表明,协调的适应性-固有免疫动态是治疗疗效的基础,而系统性免疫耗竭和髓系免疫调节则导致耐药。将这些外周免疫程序投射到独立的I-SPY2中,显示出与肿瘤免疫表型和病理完全缓解的一致关联,支持了这些发现的普遍性。我们的研究证明了整合方法在将外周免疫状态组织与机制性见解联系起来方面的实用性,为TNBC中的应答提供了信息。
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited treatment options and response to immune checkpoint inhibitors. Tumor-infiltrating lymphocytes have been extensively studied; however, the integration of peripheral immune dynamics with mechanistic regulation underlying therapeutic response remain poorly defined. Here, we integrate immune-state modeling with pathway-level mechanistic inference to analyze single-cell RNA sequencing of PBMCs from patients with advanced TNBC treated with paclitaxel alone or in combination with the anti-PD-L1 Ab atezolizumab. This framework leverages treatment arm, longitudinal sampling, and clinical response to resolve coordinated immune programs across lymphoid and myeloid compartments. We identified distinct treatment- and response-specific states before and after treatment. Chemotherapy responders displayed pretreatment adaptive immune priming, whereas combination-therapy responders exhibited preexisting effector T-cell activity coupled with tumor PD-L1 expression. In contrast, chemotherapy nonresponders developed persistent post-treatment immune dysregulation in regulatory and terminal effector programs, whereas combination-therapy nonresponders demonstrated maladaptive remodeling of adaptive and innate compartments, including dysfunctional NK and metabolically reprogrammed myeloid populations. Across regimens, pathways involving protein translation, metabolic adaptation, and stress signaling emerged as shared modulators of response. These findings suggest that coordinated adaptive-innate immune dynamics underlie therapeutic efficacy, whereas systemic immune exhaustion and myeloid immunoregulation lead to resistance. Projection of these peripheral immune programs onto independent I-SPY2 showed concordant associations with tumor immune phenotypes and pathological complete response, supporting generalizability of the findings. Our study demonstrates the utility of an integrative approach for linking peripheral immune state organization with mechanistic insights, informing response in TNBC.
MEMBER ACCOUNT
登录成功会直接打开下一页。